Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study
Authors:
- André MattarAndré Mattar
- Marcelo AntoniniMAMarcelo Antonini
- Marina Diógenes TeixeiraMTMarina Diógenes Teixeira
- Cristiano Augusto Andrade de ResendeCRCristiano Augusto Andrade de Resende
- Francisco Pimentel CavalcanteFCFrancisco Pimentel Cavalcante
- Felipe ZerwesFZFelipe Zerwes
- Renata ArakelianRARenata Arakelian
- Eduardo de Camargo MillenEMEduardo de Camargo Millen
- Fabricio Palermo BrenelliFBFabricio Palermo Brenelli
- Antonio Luiz FrassonAFAntonio Luiz Frasson
- 1 February 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400340
Abstract
PURPOSE: Triple-negative breast cancer (TNBC) presents notable treatment difficulties, especially in the public health care systems of low- and middle-income countries where access to advanced therapies is restricted. This study investigates TNBC's clinical, epidemiologic, and economic effects on survival within Brazil's public health care system. METHODS: We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those receiving neoadjuvant or adjuvant treatment, patients with or without complete pathologic response, Black and non-Black patients, and those treated with or without carboplatin-based therapy. Cox proportional hazards models were applied to estimate hazard ratios (HRs) with 95% CIs, and annual treatment costs were calculated per stage. RESULTS: Among 1,266 patients with TNBC, 710 met eligibility criteria. Kaplan-Meier analysis indicated stage II patients had a 47% lower mortality risk than stage III (HR, 0.53 [95% CI, 0.33 to 0.85]; P = .009). Patients in the adjuvant treatment group had a reduced risk (HR, 0.48 [95% CI, 0.34 to 0.69]) compared with the neoadjuvant group. Achieving complete pathologic response (pCR) greatly improved OS (HR, 0.21 [95% CI, 0.11 to 0.43]; P < .001). Black patients had better survival rates than non-Black (HR, 0.58 [95% CI, 0.40 to 0.86]; P = .006). Carboplatin use did not significantly affect OS (HR, 0.96 [95% CI, 0.65 to 1.43]; P = .857). The average monthly cost for systemic TNBC treatment increased with disease progression, from $101.87 in US dollars (USD) for stage I to $314.77 USD for stage IV second-line therapy. CONCLUSION: This study provides insight into TNBC in Brazil's public health system, showing that OS decreases with disease progression but is higher among Black patients. pCR and adjuvant therapy improve survival, although costs increase significantly at advanced stages, highlighting the economic burden of late-stage TNBC management.Keywords
This publication has 28 references indexed in Scilit:
- Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast CancerJAMA Network Open, 2023
- ESMO Guidance for Reporting Oncology real-World evidence (GROW)Annals of Oncology, 2023
- Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survivalThe Breast, 2023
- Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature ReviewPharmacoEconomics, 2022
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisAnnals of Oncology, 2021
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerAnnals of Oncology, 2021
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialThe Lancet, 2020
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerJAMA Oncology, 2020
- Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort studyThe Breast, 2019
- Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancerBreast Cancer Research and Treatment, 2016